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Background: Previous qualitative research has revealed that people with fibromyalgia use daytime napping as a
coping strategy for managing symptoms against clinical advice. Yet there is no evidence to suggest whether
daytime napping is beneficial or detrimental for people with fibromyalgia. The purpose of this study was to explore
how people use daytime naps and to determine the links between daytime napping and symptom severity in
fibromyalgia syndrome.
Methods: A community based sample of 1044 adults who had been diagnosed with fibromyalgia syndrome by a
clinician completed an online questionnaire. Associations between napping behavior, sleep quality and fibromyalgia
symptoms were explored using Spearman correlations, with possible predictors of napping behaviour entered into
a logistic regression model. Differences between participants who napped on a daily basis and those who napped
less regularly, as well as nap duration were explored.
Results: Daytime napping was significantly associated with increased pain, depression, anxiety, fatigue, memory
difficulties and sleep problems. Sleep problems and fatigue explained the greatest amount of variance in napping
behaviour, p < 0.010. Those who engaged in daytime naps for >30 minutes had higher memory difficulties (t = −3.45)
and levels of depression (t = −2.50) than those who napped for shorter periods (<30mins) (p < 0.010).
Conclusions: Frequent use and longer duration of daytime napping was linked with greater symptom severity in
people with fibromyalgia. Given the common use of daytime napping in people with fibromyalgia evidence based
guidelines on the use of daytime napping in people with chronic pain are urgently needed.
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Fibromyalgia syndrome (FMS) is a chronic medical condi-
tion associated with an amplification of pain signals in the
central nervous system and decreased ability of the
nervous system to inhibit concomitant pain responses
[1,2]. In Europe, FMS has been estimated to affect ap-
proximately 4.7% of the general population, [3] with a high
prevalence in females (female: male ratio of 9–10:1) [4-6].
FMS is a disabling condition with patients experiencing
high levels of widespread persistent pain, fatigue, cognitive
impairment and sleep disturbance that makes it difficult
to engage in everyday activities [7,8].* Correspondence: alice.theadom@aut.ac.nz
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unless otherwise stated.In a qualitative study exploring sleep disturbance in
people with FMS, it was revealed that daytime napping
was used as a coping strategy to manage the impact of
poor sleep and replenish energy levels to enable partici-
pants to continue their daily activities [9]. Daytime nap-
ping is commonly used across cultures to recuperate
and counteract the effects of sleep deprivation [10]. In
healthy adults, it has been revealed that naps of <30 mi-
nutes lead to improvements in alertness, emotional state
and cognitive performance [11-16]. Underlying circadian
processes have been found to influence the benefits
achieved following a nap, with the greatest restorative ef-
fects revealed if naps are taken on a regular basis in the
afternoon when the most severe sleepiness and pressure
for sleep is likely to occur [10,17]. Therefore, it appears
that the duration of naps and the time of day people en-
gage in a daytime nap is linked to its effects.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ping found in healthy adults in terms of improved alert-
ness, emotional state and cognitive performance, the
impact of napping in clinical populations has received
little attention. Indeed in the pain management context,
many patients are currently advised to avoid napping
during the day due to concerns over disrupting noctur-
nal sleep patterns [18-21]. Given the interrelatedness of
symptoms in FMS, it is likely that daytime napping is in-
trinsically linked with other symptoms of the condition
[22,23]. Consequently, this study aimed to explore the
frequency and type of napping used by people with FMS
and to explore any associations between daytime nap-
ping and symptoms of the condition.Methods
Participants
Participants were eligible to take part in the study if they
were aged >18 years and had been diagnosed with FMS
by a GP or consultant. Participants were asked to pro-
vide details of their FMS diagnosis for verification. Par-
ticipants who were undertaking shift-work or who had
been diagnosed with other specific sleep disorders (e.g.,
sleep apnea or restless legs syndrome) were excluded.
Participants with other medical, mood or psychiatric dis-
orders were retained in the analysis to ensure
generalizability with the FMS population where comor-
bidities are common.Procedure
Participants were recruited through advertisements dis-
seminated by the Fibromyalgia Association UK, and
FibroAction UK. The advertisement directed participants
to an online information sheet and consent form. Once
consent was obtained, participants were asked to
complete the online questionnaire. Responses on the on-
line questionnaire were collected between September
2010 and February 2011. The study received ethical ap-
proval from the University of Surrey Departmental
Ethics Committee. Participants were asked to confirm
their consent to take part in the study by ticking a box
after being informed of the study process.
Demographic information including age, sex, marital
status, time since diagnosis, co-morbid conditions, em-
ployment status and number of children living in the
household, was collected to describe the sample popula-
tion and to explore the factors that may influence day-
time napping and sleep quality. To assess daytime
napping behaviour and FMS symptoms, a range of mea-
sures were included within the online questionnaire. To
enable the exploration of the impact of regular napping
behaviour on symptoms in FMS, participants were clas-
sified into two categories, those who reported regularlytaking a daytime nap at least once a day (or more often),
and those who engaged in naps less frequently.
Assessments
Daytime napping behaviour was assessed by asking partic-
ipants how often they took a daytime nap (> once a day,
once a day, once a week, once a month, or rarely/never).
Participants were also asked how long a nap would typic-
ally last (≤15 minutes, 16–30 minutes, 31–45 minutes,
46–60 minutes, >60 minutes), whether they planned their
naps, their reasons for taking a nap and the time of day
they typically took a nap (morning, afternoon or evening).
Nocturnal sleep quality was assessed using the Medical
Outcomes Study (MOS) Sleep Scale [24]. The MOS con-
sists of 12 items exploring the quality of nocturnal sleep.
Two subscales explore any sleep problems experienced
(Sleep Problems Index I and II). Subscale scores were
calculated by transforming the raw scores to values be-
tween 0–100. The MOS has been demonstrated to be a
well-validated and reliable measure in different clinical
populations, [24-26] and was recommended for use in
the FMS population by Salaffi et al. [27].
Fatigue was measured by the Fatigue Severity Scale
(FSS) [28]. This scale contains nine items that ask about
the severity and impact of fatigue over the preceding
week. Each item is rated on a scale ranging from 1
(strongly disagree) to 7 (strongly agree). Total scores are
calculated by summing the item responses to yield a
score between 9–63. The FSS has previously been used
in FMS, [27] and has been shown to have high internal
reliability, [28] and validity [29].
Levels of subjective pain were assessed by using the
McGill Short Form Pain Questionnaire [30]. Participants
were presented with 15 words (items) describing differ-
ent characteristics of pain and were asked to rate how
much they experience each type of pain from 0 (none)
to 3 (severe). Each item was categorized into one of two
subscales (11 sensory items and 4 affective pain items),
with the ratings for each subscale added to yield a total
score between 0–33 and 0–12, respectively. An overall
pain rating was calculated by summing all responses on
the 15 items to yield a score between 0–45.
Mood disturbance was assessed using the Hospital
Anxiety and Depression Scale (HADS) [31,32]. This
scale has been widely used for assessing levels of anx-
iety and depression in patients with medical problems.
The scale consists of 14 questions that ask participants
how often they have experienced each item (e.g., I feel
tense and wound up) over the past week on a scale of 0
(not at all) to 3 (most of the time). There are two sub-
scales (anxiety and depression) and subscale scores
range between 0–21 (0–7 normal, 8–10 mild, 11–14







included in the analysis
Excluded
N = 16 Did not provide consent for their data to be
used
N = 3 <18 years of age
N = 49 No evidence of FMS diagnosis by medical
practitioner
N = 64 Undertaking shiftwork
N = 19 Diagnosed with sleep apnea
N = 15 Diagnosed with Restless legs syndrome
N = 1 Diagnosed with Narcolepsy
N= 47 Did not complete >20% of an assessment
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Questionnaire-Revised (EMQ-R) [33]. This measure
contains 13 items which explore memory impairment in
situations that occur in everyday life. Participants were
asked to respond to each item by stating how often the
given situation has happened in the last month on a
scale of 0 (once or less per month) to 4 (once or more
in a day). Total scores were calculated by summing the
item scores (ranging from 0–52). To enable comparisons
with previous publications, the average item score has
also been reported in the current study.N = 1044
Figure 1 Participants flow diagram.Statistical analyses
All data were analyzed using SPSS Version 19.0 (SPSS
Inc., Chicago, IL, USA). Missing values were replaced
with participant mean substitution. Statistical signifi-
cance was considered at a two-tailed level of p < 0.01 to
account for the multiple statistical tests conducted.
Descriptive statistics were used to describe the sample
and distribution of scores on the assessment measures.
For variables with a skewed distribution (>0.3), medians
and interquartile ranges were reported, with Mann
Whitney U tests used to compare median values on out-
come measures between groups. For variables with data
meeting parametric assumptions, mean and standard de-
viations were reported with t-tests used to detect any
differences between groups. Chi Square tests were used
to explore differences on categorical data. Group differ-
ences were explored between daily and non-regular
nappers and also for examining differences in napping
behaviour within the daily napping group (those who
nap for less than or more than 30 minutes and also for
non-intentional versus intentional nappers). Higher scores
on all outcome measures indicate poorer outcome.
A logistic regression analysis was conducted to explore
the impact of predictors of engaging in daily napping be-
haviour. Variables were entered into the regression model
using the forward conditional method, to allow identifica-
tion of the variables that contribute most to the model.Results
Sample characteristics
A total of 1044 participants met the inclusion criteria for
this study and were included in the final analysis
(Figure 1). There was a high percentage of females in
this sample (92.5%), reflecting the increased prevalence
of FMS in the female population. Participants were aged
between 18 and 88 years, with the time in years since
diagnosis ranging between 0 and 30 years. Four percent
of the sample were excluded from the analysis because
they completed less than 80% of items on one or more
of the measures. The excluded 4%, were not found to be
significantly different from the participants who didcomplete the full questionnaire on age, gender and time
since diagnosis.
There was a high rate of co-morbid conditions
(Table 1), with the most frequent conditions including
arthritis (20%), irritable bowel syndrome (15%) and
asthma (13%). Of the sample, 5.1% reported a psychiatric
condition and 11.2% had depression. Due to the wide
range of co-morbidities reported, participants were clas-
sified as having no co-morbidity (N = 203), 2 or less co-
morbidities (N = 548) or >2 co-morbidities (N = 293). In
addition, a large proportion of the sample were taking
medication to relieve their FMS symptoms, including
painkillers (opiods), non-steroidal anti-inflammatory
medications and tricyclic antidepressants.
Analysis of only those participants who napped on a
daily basis revealed that on a typical weekday 18.9%
napped in the morning, 58.8% in the afternoon and
25.0% in the evening. It was revealed that a high propor-
tion of participants found themselves taking a nap with-
out intending to (86.5%). There were N = 235 (22.5%)
who reported that they planned when they took a daytime
nap sometimes or almost always. The most common rea-
sons for taking a nap included tiredness/exhaustion
(94.1%), feeling unwell (67.2%), to catch up from the previ-
ous night’s poor sleep (59.6%), due to headache (42.6%)
and pain (26.2%).
As sleeping patterns naturally change as people age,
napping behaviour was explored between younger adults
(N = 362) and those aged more than 60 years (N = 46).
Younger adults reported taking more daytime naps each
day (22.4% reporting taking more than one nap per day
in comparison to 13% of older adults) and a greater pro-
portion of people napping for longer (75,7% >30 minutes
in comparison to 41.3% of adults). Frequency of
intentional napping was similar for both younger and
older adults (32.3% and 32.6% respectively). Reasons for
napping were broadly similar, although more younger
adults reported napping due to pain (62.4 and 54.3% re-
spectively) and feeling irritable (65.4% and 52.2%), with a
Table 1 Sample characteristics
Median Interquartile
range
Duration since symptom onset in years 7.0 10.0
Years since diagnosis 3.0 6.0
McGill Pain questionnaire (range 0–45) 30.0 11.0
Frequency Percentage
Marital status
Married or living with partner 733 70.2
Separated/divorced/widowed 192 18.4
Single 119 11.4
Taking medication for FMS 885 84.8
Diagnosed co-morbid condition/s 844 80.8
In current employment 386 37.0
Napping behaviour
Regularly nap once a day or more 408 39.1




MOS Sleep problems index I (range 0–100) 65.2 17.0
MOS Sleep problems index II (range 0–100) 66.9 16.7
Fatigue severity score (range 9–63) 55.3 9.9
HADS Anxiety subscale (range 0–21) 12.2 4.4
HADS Depression subscale (range 0–21) 10.4 4.1
EMQ-R Everyday memory
Total memory score (range 0–52) 32.74 13.5
Item score (Mean) (range 0–4) 2.52 1.0
Theadom et al. BMC Musculoskeletal Disorders  (2015) 16:13 Page 4 of 9greater proportion of older adults using napping to help
them feel revitalized (younger adults 47.5% and 65.2% of
older adults).Relationships between daytime napping and FMS
symptoms
Bivariate correlations revealed that daytime napping was
significantly positively associated with the number of co-
morbidities rho = .12, levels of fatigue rho = .22, and pain
rho = .19, anxiety rho = .12, depression rho = .18, sleep
problems rho = .26, and frequent everyday memory diffi-
culties rho = .18, p < 0.01.
To explore if medication use may be impacting on our
findings, respective associations were explored between
daytime napping and type of medication used. Daytime
napping was significantly positively correlated with use of
serotonin-norepinephrine reuptake inhibitors or selective
serotonin reuptake inhibitors, rho = .10, Pregabalin or
Gabapentin, rho = .10 and opioids, rho = .14 (p < 0.01),
but not with other types of medications (tricyclicantidepressants, non-steroidal anti-inflammatories, hyp-
notics and other medications).
Differences between regular daily nappers and those who
nap less regularly
To explore differences in symptom severity in partici-
pants who regularly engaged in daily napping behavior
and those who napped less regularly or not at all, differ-
ences between scores across the assessment measures
were calculated (Table 2). It was revealed that partici-
pants who regularly napped on a daily basis had a higher
number of comorbidities, higher levels of pain, and fa-
tigue, memory difficulties, sleep problems, anxiety and
depression (p < 0.001).
Differences between those who take long or short naps
daily
To elucidate if the length of time people napped also af-
fected the impact of daytime napping, differences between
those napping for <30 minutes and those >30 minutes
each day were calculated. Of the participants who re-
ported taking a daytime nap at least once per day, partici-
pants who typically napped for longer than 30 minutes
were younger in age, with children living in the household
and had significantly higher levels of depression and mem-
ory difficulties, in comparison to participants who napped
for shorter periods of time (Table 3). It was also observed
that those who did not intend to nap had higher levels of
pain and depression than intentional nappers.
Predictors of daily napping behaviour
Variables significantly correlated with napping outcome
were entered into a logistic regression model using the
forward conditional method. As both sleep problem in-
dexes (Index I and II of the MOS) were highly correlated
with each other, only the more comprehensive sleep
problems index (Index II) was entered into the regres-
sion model. The Nagelkerke R square of 0.91 indicated a
strong relationship between predictors and group mem-
bership of those who napped daily or not. The overall
success rate of the model to correctly classify partici-
pants was 65.4%. The Wald criterion demonstrated that
sleep problems contributed most to the variance in the
model (Table 4). Age, number of children living in the
household and number of comorbidities, use of Pregaba-
lin or Gabapentin or antidepressants (yes or no), levels
of anxiety, depression, pain and everyday memory did
not significantly contribute to the final model. Being
male, sleep problems and fatigue significantly predicted
daytime napping behavior in the final model (p < 0.010).
Discussion
The findings of this study revealed that daytime napping
was associated with greater symptom severity in people
Table 2 Comparisons between those who nap daily on a regular basis and those who do not
Regular daily nap (N = 408) Non regular nap (N = 636) Test of difference
Median (Interquartile range)
Number of children 1.00 (2.00) 0.00 (2.00) U = 3.02, P = 0.82
Years since diagnosis 7.00 (10.00) 7.00 (9.00) U = 0.50, p = 0.52
McGill Pain questionnaire
Sensory subscale (Median, IQR) 24.00 (7.00) 22.00 (7.00) U = 102,640, p = 0.00
Affective subscale (Median, IQR) 8.00 (4.00) 7.00 (4.00) U = 105,928, p = 0.00
Total score median (Median, QR) 32.00 (9.75) 29.00 (11.00) U = 101,372, p = 0.00
Frequency (%)
Male gender 41 (10%) 37 (5.8%) χ = 6.44, p = 0.01
Number of co-morbidities
None 63 (15.4%) 140 (22.0%) Χ = 13.83, p = 0.00
≤2 Co-morbidities 207 (50.7%) 341 (53.6%)
>2 Co-morbidities 138 (33.8%) 155 (24.4%)
Mean
(Standard deviation)
Age 47.17 (10.08) 46.75 (10.59)
MOS Sleep outcomes scale
Sleep duration in hours 5:47 (01:57) 6:04 (01:48) t = 2.45, p = 0.02
Sleep problems index I 70.65 (15.61) 61.65 (16.95) t =8.63, p = 0.00
Sleep problems index II 72.20 (15.28) 63.42 (16.71) t =8.57, p = 0.00
FSS Fatigue severity
Total score 57.67 (8.42) 53.72 (10.47) t = −6.41, p = 0.00
EMQ-R Everyday memory
Total score 35.61 (12.86) 30.91 (13.51) t = −5.59, p = 0.00
HADS Mood
Anxiety subscale 12.84 (4.27) 11.77 (4.37) t = −3.89, p = 0.00
Depression subscale 11.36 (3.90) 9.83 (14.14) t = −5.94, p = 0.00
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nap were found to have a higher number of co-
morbidities, increased levels of pain, fatigue, sleep prob-
lems, memory difficulties, and mood disturbance in
comparison to participants with FMS who napped less
regularly or not at all. The duration of naps was found
to have an influence on the impact of symptoms, with
participants who napped >30 minutes on a daily basis
found to be younger, to have children living in the
household and to have greater levels of depression and
memory difficulties. Sleep problems and levels of fatigue
contributed most to the prediction of engaging in day-
time naps in participants with FMS.
The most common reasons for napping included tired-
ness/exhaustion, feeling unwell, to catch up from the
previous night’s poor sleep, and in response to having a
headache and high levels of pain, supporting the notion
that napping is used as a coping strategy in FMS. It is of
concern that a high proportion of people taking a napregularly on a daily basis, did so without intending to,
suggesting the influence of underlying sleep processes
on napping behaviour and people’s difficulty in
remaining wakeful during the day. This was also
highlighted through the findings that those who did not
intent to nap experienced higher levels of pain and de-
pression. The high frequency of taking a nap in the
afternoon suggests that this may be a particularly chal-
lenging time of the day for people with FMS, when they
are fatigued after expending their energy resources dur-
ing the morning, in addition to the increase in sleep
pressure experienced at this time of day. This suggests
that patients need support in managing afternoon pe-
riods and offers support to the proposal that there is a
need to tailor the recommended timing of sleep to indi-
vidual sleep chronotypes and sleep patterns [17,34].
The finding that men nap more frequently than
women, and that longer duration of naps were associ-
ated with poorer health outcomes such as increased
Table 3 Differences in outcome measures between different napping behaviour for those who engage in a daytime nap at least once per day










Age (Mean) 50.63 (10.73) 45.82 (9.50) t = 4.44, p = 0.00 47.67 (9.40) 46.94 (10.40) t = 0.71, p 0.48
Sex (% Male) 8 (7.0%) 33 (11.3%) Χ = 1.6, p = 0.19 12 (9.10) 29 (10.5) X = 0.20, p = 0.66
Median number of children 0.00 (1.00) 1.00 (2.00) U = 9.69, p = 0.03 1.00 (2.00) 0.00 (2.00) U = 0.00, p = 1.00
Median years since diagnosis 7.00 (9.00) 8.00 (10.00) U = 16,902, p = 0.84 3.5 (5.0) 3.0 (5.0) U = 0.01, p = 0.98
Number of co-morbidities
None (N, %) 17 (14.8%) 46 (15.7%) Χ =0.34, p = 0.84 17 (12.9) 46 (16.7) X = 1.20, p = 0.55
≤2 comorbidities (N, %) 61 (53.0%) 146 (49.8%) 71 (53.8) 136 (49.3)
>2 comorbidities (N, %) 37 (32.2%) 101 (34.5%) 44 (33.3) 94 (34.1)
MOS Sleep outcomes scale
Mean sleep duration in hours 5:32 (01:38) 5:52 (02:03) t = −1.61, p = 0:11 6:02 (1:58) 5:39 (1:56) t = −1.78, p = 0.08
Mean sleep problems index I 69.94 (16.45) 70.93 (15.29) t = −0.58, p = 0.57 50.78 (16.34) 46.87 (14.48) t = 3.55, p = 0.00
Mean sleep problems index II 70.98 (16.54) 72.68 (14.76) t = −1.01, p = 0.31 45.03 (12.73) 42.00 (10.84) t = 4.02, p = 0.00
McGill Pain questionnaire
Median sensory subscale 25.00 (8.00) 24.00 (6.50) U = 16,817, p = 0.82 22.00 (11.00) 25.00 (7.00) U = 21.11, p = 0.00
Median affective subscale 8.00 (4.00) 8.00 (4.00) U = 17,714, p = 0.81 7.5 (4.0) 8.00 (4.00) U = 4.35, p = 0.04
Median total score 33.00 (11.00) 32.00 (10.00) U = 17,342, p = 0.64 30.00 (9.00) 31.98 (9.00) U = 22.45, p = 0.00
FSS Fatigue severity
Mean total score 56.72 (9.09) 58.05 (8.13) t = −1.43, p = 0.15 57.67 (8.36) 57.67 (8.57) t = 252.45, p = 1.00
EMQ-R Everyday memory
Mean total score 32.15 (14.07) 36.97 (12.11) t = −3.45, p = 0.00 29.55 (6.64) 31.98 (7.08) t = 272.37, p = 0.10
HADS Mood
Mean anxiety score 12.13 (4.44) 13.11 (4.18) t = −2.10, p = 0.04 12.30 (4.05) 13.12 (4.39) t = 2.22, p = 0.03
Mean depression score 10.59 (3.99) 11.66 (3.84) t = −2.50, p = 0.01 10.75 (3.42) 11.60 (4.01) t = 2.72, p = 0.01













Table 4 Logistic regression analyses
B Standard error Wald Sig. Exp (B) Lower confidence interval (95%) Upper confidence interval (95%)
Gender −0.72 0.25 8.25 0.00 0.49 0.30 0.80
Use of opiods 0.36 0.14 6.81 0.01 1.43 1.09 1.88
Sleep problems 0.03 0.01 36.92 0.00 1.03 1.02 1.04
Fatigue 0.04 0.01 18.14 0.00 1.04 1.02 1.06
Constant −3.99 0.55 52.57 0.00 .02
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haviour in older adults [35]. Previous studies have re-
vealed that frequency of napping behaviour increases
with age [36]. However, it was interesting that in this
study, age was not found to be positively associated or
predictive of daytime napping behaviour in FMS, even
with 11.5% of the sample aged over 60 years. Moreover,
it was observed that younger adults with FMS napped
more frequently and for longer periods of time than
older adults; with a higher proportion of younger adults
reporting napping due to pain and irritability. These
findings suggests that napping behaviour may be more
intrinsically linked to FMS symptoms than other demo-
graphic factors, however causality was unable to be de-
termined within this study. This highlights the
potential unique characteristics of napping behaviour
in clinical populations.
Levels of sleep difficulties, fatigue and pain were
revealed to be high, consistent with other studies ex-
ploring the symptom profile of people with FMS
[7,37-39]. In addition, medication was found to be
linked to frequency of daytime napping and may reflect
the higher levels of symptoms experienced by partici-
pants. As a high proportion of people with FMS require
medication, excluding such participants from the study
would have biased the sample. However, due to the
wide range of medications taken to manage symptoms
of the FMS, quantifying medication use proved challen-
ging. The impact of medication use was therefore ex-
plored in this study by looking at the impact of
different types of medication on napping behaviour,
however more detailed investigation on the effect of
varying dosages and brands of medication is warranted.
This study only explored napping behaviour within
those who napped on a daily basis due to the difficul-
ties in accurately assessing napping behaviour used on
a less frequent basis which can highly variable [40].
Self-reported napping behaviour has been found to un-
derreport actual napping behaviour, and therefore the
present findings may well underestimate actual nap-
ping behaviour. Studies using daily sleep diaries or
objective measurements of daytime napping such as
wrist actigraphy are needed to support our findings.
And more objective methods will assist in determining
causality of associations identified and aid ourunderstanding of the impact of less regular napping
behavior on FMS symptoms. Although participants
identified as having a sleep disorder were excluded
from this study, it is recognized that a high proportion
of sleep disorders are undiagnosed which may have in-
fluenced our findings. Screening tools for sleep disor-
ders would also be useful to include in further
research studies of sleep and FMS.
The findings that daytime napping, nocturnal sleep,
medication use and symptoms of FMS including fatigue
were highly interlinked suggests that there is a need to
address the issue of daytime napping in pain manage-
ment programmes and specific interventions may need
to be developed. It is apparent that there is a lot of con-
flicting advice currently being given to patients, with
23% of participants being recommended to take a day-
time nap by a health professional whilst others received
no advice or were advised not to nap. It is important
that clinical advice is informed by the research evidence
and further research is needed to determine whether
taking a daytime nap is a beneficial coping strategy or
not and if it is, how to use napping most effectively (e.g.
time of day and duration of nap) to inform clinical
recommendations [41].
To date, the diagnosis of FMS is based on the American
College of Rheumatology (ACR) criteria [6]. Recently,
a number of limitations of these criteria have been
published suggesting revising these diagnostic proce-
dures to better accommodate the full range of symp-
toms associated with FMS. However, these revised
criteria still require further investigation and validation
in clinical practice [42]. In response to these chal-
lenges with diagnostic criteria, participants were re-
cruited into the current study if they had been
diagnosed by a clinician, and were required to provide
details of their diagnosis for verification. This ap-
proach may therefore be subject to inconsistencies in
diagnostic accuracy between clinicians. Despite these
limitations, the current study is strengthened by its
large sample size and inclusion of both men and
women with FMS. This study clearly highlights the
need to increase understanding the role of daytime
napping in people with FMS and its likely impact on
other clinical populations experiencing high levels of
poor sleep, pain and fatigue.
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Greater frequency and duration of daytime napping was
associated with more severe symptomology in FMS. The
majority of participants reported using daytime napping as
a strategy for coping with poor sleep and FMS symptoms.
Further research is needed to understand if daytime nap-
ping is detrimental to symptom severity or if it can be rec-
ommended as a strategy to manage symptoms in FMS.
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